Tod Smeal

17.1k total citations · 9 hit papers
52 papers, 12.9k citations indexed

About

Tod Smeal is a scholar working on Molecular Biology, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Tod Smeal has authored 52 papers receiving a total of 12.9k indexed citations (citations by other indexed papers that have themselves been cited), including 38 papers in Molecular Biology, 21 papers in Oncology and 9 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Tod Smeal's work include Protein Kinase Regulation and GTPase Signaling (12 papers), Melanoma and MAPK Pathways (7 papers) and PI3K/AKT/mTOR signaling in cancer (6 papers). Tod Smeal is often cited by papers focused on Protein Kinase Regulation and GTPase Signaling (12 papers), Melanoma and MAPK Pathways (7 papers) and PI3K/AKT/mTOR signaling in cancer (6 papers). Tod Smeal collaborates with scholars based in United States, France and United Kingdom. Tod Smeal's co-authors include Michael Karin, Peter Angel, Audrey Minden, Michael Karin, Anning Lin, Bernard Binétruy, Tony Hunter, Masahiko Hibi, William J. Boyle and Kazue Hattori and has published in prestigious journals such as Nature, Cell and Proceedings of the National Academy of Sciences.

In The Last Decade

Tod Smeal

52 papers receiving 12.7k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Identification of an oncoprotein- and UV-responsive protein kinase that binds and potentiates the c-Jun activation domain.

1993 1.7k citations Tod Smeal, Michael Karin et al. profile →
Transcriptional interference between c-Jun and the glucocorticoid receptor: Mutual inhibition of DNA binding due to direct protein-protein interaction

1990 1.4k citations Hsin‐Fang Yang‐Yen, Jean‐Claude Chambard et al. Cell profile →
The c-fos protein interacts with c-JunAP-1 to stimulate transcription of AP-1 responsive genes

1988 1.2k citations Tod Smeal, Michael Karin et al. Cell profile →
The jun proto-oncogene is positively autoregulated by its product, Jun/AP-1

1988 1.1k citations Peter Angel, Kazue Hattori et al. Cell profile →
Activation of protein kinase C decreases phosphorylation of c-Jun at sites that negatively regulate its DNA-binding activity

1991 949 citations Tod Smeal, Peter Angel et al. Cell profile →
The mammalian ultraviolet response is triggered by activation of src tyrosine kinases

1992 772 citations Yoram Devary, Roberta A. Gottlieb et al. Cell profile →
Oncogenic and transcriptional cooperation with Ha-Ras requires phosphorylation of c-Jun on serines 63 and 73

1991 716 citations Tod Smeal, Bernard Binétruy et al. Nature profile →
Activation of cAMP and mitogen responsive genes relies on a common nuclear factor

1994 651 citations Tod Smeal, Michael Karin et al. Nature profile →
Ha-Ras augments c-Jun activity and stimulates phosphorylation of its activation domain

1991 572 citations Bernard Binétruy, Tod Smeal et al. Nature profile →

Peers

Countries citing papers authored by Tod Smeal

Since Specialization

Citations

This map shows the geographic impact of Tod Smeal's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tod Smeal with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tod Smeal more than expected).

Fields of papers citing papers by Tod Smeal

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tod Smeal. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tod Smeal. The network helps show where Tod Smeal may publish in the future.

Co-authorship network of co-authors of Tod Smeal

This figure shows the co-authorship network connecting the top 25 collaborators of Tod Smeal. A scholar is included among the top collaborators of Tod Smeal based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tod Smeal. Tod Smeal is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Abstract PO2-04-09: Combination of the PLK1 Inhibitor Onvansertib and the PI3Kα Inhibitor Alpelisib Overcomes Palbociclib Resistance in PIK3CA-mutated HR+ Breast Cancer 2024 ·Cancer Research ·Sreeja Sreekumar, Pierre Painsec, (unknown), (unknown), Laura Sourd, Élodie Montaudon, Tod Smeal, Elisabetta Marangoni, Maya Ridinger	1
2	Onvansertib in Combination With Chemotherapy and Bevacizumab in Second-Line Treatment of KRAS -Mutant Metastatic Colorectal Cancer: A Single-Arm, Phase II Trial 2024 ·Journal of Clinical Oncology ·Daniel H. Ahn, Maya Ridinger, Timothy Lewis Cannon, (unknown), Jason S. Starr, Joleen M. Hubbard, Anup Kasi, Afsaneh Barzi, Errin Samuëlsz, Anju Karki, Ramanand A. Subramanian, (unknown), Roy Kim, (unknown), Peter J.P. Croucher, Tod Smeal, Fairooz F. Kabbinavar, Heinz‐Josef Lenz	11
3	PLK1 Inhibitor Onvansertib Enhances the Efficacy of Alpelisib in PIK3CA-Mutated HR-Positive Breast Cancer Resistant to Palbociclib and Endocrine Therapy: Preclinical Insights 2024 ·Cancers ·Sreeja Sreekumar, Élodie Montaudon, (unknown), (unknown), Pierre Painsec, (unknown), Laura Sourd, Tod Smeal, Elisabetta Marangoni, Maya Ridinger	1
4	Targeting the CXCR4 pathway using a novel anti-CXCR4 IgG1 antibody (PF-06747143) in chronic lymphocytic leukemia 2017 ·Journal of Hematology & Oncology ·Manoj Kumar Kashyap, (unknown), Deepak Kumar, Brett H. Simmons, Nanni Huser, Yin Gu, Max Hallin, Kevin C. Lindquist, (unknown), Michael Y. Choi, (unknown), Laura Z. Rassenti, Cathy Zhang, Shu‐Hui Liu, Tod Smeal, Valeria R. Fantin, Thomas J. Kipps, Flavia Pernasetti, Januario E. Castro	49
5	The ALK/ROS1 Inhibitor PF-06463922 Overcomes Primary Resistance to Crizotinib in ALK-Driven Neuroblastoma 2015 ·Cancer Discovery ·Nicole R. Infarinato, Jin H. Park, Kateryna Krytska, Hannah T. Ryles, Renata Sano, (unknown), Yimei Li, Helen Y. Zou, Nathan V. Lee, Tod Smeal, Mark A. Lemmon, Yaël P. Mossé	116
6	Mechanistic Understanding of Translational Pharmacokinetic-Pharmacodynamic Relationships in Nonclinical Tumor Models: A Case Study of Orally Available Novel Inhibitors of Anaplastic Lymphoma Kinase 2014 ·Drug Metabolism and Disposition ·Shinji Yamazaki, Justine L. Lam, Helen Y. Zou, Hui Wang, Tod Smeal, Paolo Vicini	15
7	Translational Pharmacokinetic-Pharmacodynamic Modeling for an Orally Available Novel Inhibitor of Anaplastic Lymphoma Kinase and c-Ros Oncogene 1 2014 ·Journal of Pharmacology and Experimental Therapeutics ·Shinji Yamazaki, Justine L. Lam, Helen Y. Zou, Hui Wang, Tod Smeal, Paolo Vicini	19
8	Epithelial Tissue Hyperplasia Induced by the RAF Inhibitor PF-04880594 Is Attenuated by a Clinically Well-Tolerated Dose of the MEK Inhibitor PD-0325901 2012 ·Molecular Cancer Therapeutics ·(unknown), Donald Wojciechowicz, Wenyue Hu, (unknown), Winston Evering, (unknown), Lisa D. Marroquin, Tod Smeal, Shinji Yamazaki, Cynthia L. Palmer, Leigh Ann Burns‐Naas, Shubha Bagrodia	8
9	Biomarker and Pharmacologic Evaluation of the γ-Secretase Inhibitor PF-03084014 in Breast Cancer Models 2012 ·Clinical Cancer Research ·Cathy C. Zhang, Adam Pavlı́c̀ek, Qin Zhang, Maruja E. Lira, Cory L. Painter, Zhengming Yan, Xianxian Zheng, Nathan V. Lee, Mark Ozeck, Ming Qiu, (unknown), Patrick B. Lappin, Anthony Wong, Paul A. Rejto, Tod Smeal, James G. Christensen	53
10	Sensitivity of Selected Human Tumor Models to PF-04217903, a Novel Selective c-Met Kinase Inhibitor 2012 ·Molecular Cancer Therapeutics ·Helen Y. Zou, Qiuhua Li, Joseph H. Lee, Maria E. Arango, (unknown), Ming Qiu, Lars D. Engstrom, Shinji Yamazaki, (unknown), Sergei Timofeevski, Jingrong Jean Cui, Michele McTigue, Gerrit Los, Steven L. Bender, Tod Smeal, James G. Christensen	57
11	Small-molecule p21-activated kinase inhibitor PF-3758309 is a potent inhibitor of oncogenic signaling and tumor growth 2010 ·Proceedings of the National Academy of Sciences ·Brion W. Murray, Chuangxing Guo, Joseph Piraino, John Westwick, Cathy Zhang, Jane E. Lamerdin, Eleanor Dagostino, (unknown), Cho‐Ming Loi, Michael Zager, Eugenia Kraynov, Ian Popoff, James G. Christensen, (unknown), Susan E. Kephart, Joseph Marakovits, (unknown), Simon Bergqvist, Tod Smeal	253
12	Evaluation of Selective γ-Secretase Inhibitor PF-03084014 for Its Antitumor Efficacy and Gastrointestinal Safety to Guide Optimal Clinical Trial Design 2010 ·Molecular Cancer Therapeutics ·Ping Wei, Marlena Walls, Ming Qiu, (unknown), Robert H. Denlinger, Anthony Wong, (unknown), Jitesh P. Jani, Natilie Hosea, Michelle Sands, Sophia Randolph, Tod Smeal	158
13	Dihydroxylphenyl amides as inhibitors of the Hsp90 molecular chaperone 2008 ·Bioorganic & Medicinal Chemistry Letters ·Pei‐Pei Kung, Lee Funk, Jerry Meng, Michael Collins, Joe Z. Zhou, M. Catherine Johnson, Anne Ekker, Jeff Wang, Pramod P. Mehta, Min-Jean Yin, Caroline Rodgers, Jay F. Davies, (unknown), Tod Smeal, Karen A. Maegley, Michael R. Gehring	38
14	Loss of Transcriptional Silencing Causes Sterility in Old Mother Cells of S. cerevisiae 1996 ·Cell ·Tod Smeal, J. Claus, Brian K. Kennedy, Francesca Cole, Leonard Guarente	235
15	Oncoprotein-Mediated Signalling Cascade Stimulates c-Jun Activity by Phosphorylation of Serines 63 and 73 1992 ·Molecular and Cellular Biology ·Tod Smeal, Bernard Binétruy, Daniel A. Mercola, (unknown), Gisela Heidecker, Ulf R. Rapp, Michael Karin	80
16	The mammalian ultraviolet response is triggered by activation of src tyrosine kinases breakdown → 1992 ·Cell ·Yoram Devary, Roberta A. Gottlieb, Tod Smeal, Michael Karin	772
17	Control of transcription factors by signal transduction pathways: the beginning of the end 1992 ·Trends in Biochemical Sciences ·Michael Karin, Tod Smeal	317
18	Ha-Ras augments c-Jun activity and stimulates phosphorylation of its activation domain breakdown → 1991 ·Nature ·Bernard Binétruy, Tod Smeal, Michael Karin	572
19	Transcriptional interference between c-Jun and the glucocorticoid receptor: Mutual inhibition of DNA binding due to direct protein-protein interaction breakdown → 1990 ·Cell ·Hsin‐Fang Yang‐Yen, Jean‐Claude Chambard, (unknown), Tod Smeal, Thomas J. Schmidt, Jacques Drouin, Michael Karin	1389
20	The jun proto-oncogene is positively autoregulated by its product, Jun/AP-1 breakdown → 1988 ·Cell ·Peter Angel, Kazue Hattori, Tod Smeal, Michael Karin	1129

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact